AZN.UK

10,328

+1.65%↑

GSK

1,398

+2.61%↑

INDV

835

+1.46%↑

AZN.UK

10,328

+1.65%↑

GSK

1,398

+2.61%↑

INDV

835

+1.46%↑

AZN.UK

10,328

+1.65%↑

GSK

1,398

+2.61%↑

INDV

835

+1.46%↑

AZN.UK

10,328

+1.65%↑

GSK

1,398

+2.61%↑

INDV

835

+1.46%↑

AZN.UK

10,328

+1.65%↑

GSK

1,398

+2.61%↑

INDV

835

+1.46%↑

Search

Haleon PLC

Chiusa

SettoreSettore sanitario

403.1 0.6

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

400.6

Massimo

406.4

Metriche Chiave

By Trading Economics

Entrata

-254M

231M

Vendite

-21M

2.8B

P/E

Media del settore

24.919

56.602

EPS

0.042

Rendimento da dividendi

1.66

Margine di Profitto

8.373

Dipendenti

24,561

EBITDA

-317M

399M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+5.65% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

1.66%

2.45%

Utili prossimi

31 lug 2025

Prossima data del' Ex Dividendo

14 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

1.9B

36B

Apertura precedente

402.5

Chiusura precedente

403.1

Notizie sul Sentiment di mercato

By Acuity

31%

69%

88 / 382 Classifica in Healthcare

Haleon PLC Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

15 apr 2025, 09:37 UTC

Acquisizioni, Fusioni, Takeovers

Haleon Acquires Chinese JV in $264 Million Deal

19 mar 2025, 07:34 UTC

Acquisizioni, Fusioni, Takeovers

Pfizer Sells Remaining 7.3% Haleon Shareholding for $3.25 Billion

18 mar 2025, 17:26 UTC

Acquisizioni, Fusioni, Takeovers

Pfizer to Dispose of Remaining Shareholding in Haleon

30 apr 2025, 08:33 UTC

Discorsi di Mercato
Utili

Haleon's Vitamins & Supplements Business Weakness in Focus Among Results -- Market Talk

30 apr 2025, 06:09 UTC

Utili

Haleon Expects Macroeconomic Environment to Remain Challenging, Uncertain

30 apr 2025, 06:09 UTC

Utili

Haleon Continues to Deliver Against Capital Allocation Priorities

30 apr 2025, 06:08 UTC

Utili

Analysts Saw Haleon 1Q Organic Revenue Growth at 5.1%

30 apr 2025, 06:03 UTC

Utili

Haleon Sees 2025 Adjusted Operating Profit Growth Ahead of Revenue Growth

30 apr 2025, 06:03 UTC

Utili

Haleon Sees 2025 Organic Revenue Growth of 4%-6%

30 apr 2025, 06:03 UTC

Utili

Haleon Backs 2025 View

30 apr 2025, 06:03 UTC

Utili

Haleon 1Q Rev GBP2.85B

30 apr 2025, 06:01 UTC

Utili

Haleon 1Q Organic Revenue Growth up 3.5%

29 apr 2025, 19:47 UTC

Utili

Pfizer Shares Rise on CEO's Optimism on Threatened Drug Tariffs -- Barrons.com

15 apr 2025, 09:03 UTC

Acquisizioni, Fusioni, Takeovers

Haleon: Deal Expected to Close Within Next Three Mos

15 apr 2025, 09:03 UTC

Acquisizioni, Fusioni, Takeovers

Haleon Has Bought Last 12% Interest for GBP200M

15 apr 2025, 09:02 UTC

Acquisizioni, Fusioni, Takeovers

Haleon Bought 33% interest in December 2024

15 apr 2025, 09:02 UTC

Acquisizioni, Fusioni, Takeovers

Haleon Buys 33% Interest in Tianjin TSKF Pharmaceutical from Tianjin Pharmaceutical Da Ren Tang

15 apr 2025, 09:01 UTC

Acquisizioni, Fusioni, Takeovers

Haleon Buys 33% Interest in Tianjin TSKF Pharmaceutical

18 mar 2025, 16:58 UTC

Acquisizioni, Fusioni, Takeovers

Haleon Intends to Cancel Purchased Ordinary Shares

18 mar 2025, 16:57 UTC

Acquisizioni, Fusioni, Takeovers

Citigroup: Off-Market Transaction Will Close at Same Time as or Following Settlement of Offering

18 mar 2025, 16:56 UTC

Acquisizioni, Fusioni, Takeovers

Citigroup: Off-Market Purchase Worth Approx GBP170M in Ordinary Shares

18 mar 2025, 16:56 UTC

Acquisizioni, Fusioni, Takeovers

Citigroup: Haleon Agreed to Carry out Off-Market Purchase From Pfizer

18 mar 2025, 16:52 UTC

Acquisizioni, Fusioni, Takeovers

Haleon Takes Note of Announcement

18 mar 2025, 16:50 UTC

Acquisizioni, Fusioni, Takeovers

Citigroup: Haleon Won't Receive Any Net Proceeds From Offering

18 mar 2025, 16:50 UTC

Acquisizioni, Fusioni, Takeovers

Citigroup: This Is Subject to Customary Closing Conditions

18 mar 2025, 16:50 UTC

Acquisizioni, Fusioni, Takeovers

Citigroup: Pfizer Will Receive All of Net Proceeds From Offering

18 mar 2025, 16:49 UTC

Acquisizioni, Fusioni, Takeovers

Citigroup: Bookbuilding Period May Close at Any Time on Short Notice

18 mar 2025, 16:49 UTC

Acquisizioni, Fusioni, Takeovers

Citigroup: Bookbuilding Period Will Commence Immediately

18 mar 2025, 16:49 UTC

Acquisizioni, Fusioni, Takeovers

Citigroup: Price Per Sale Share to Be Determined Through Accelerated Bookbuilding Process

18 mar 2025, 16:48 UTC

Acquisizioni, Fusioni, Takeovers

Citigroup: Pfizer Intends to Sell Ordinary Shares to Institutional Investors

Confronto tra pari

Modifica del prezzo

Haleon PLC Previsione

Obiettivo di Prezzo

By TipRanks

5.65% in crescita

Previsioni per 12 mesi

Media 416.67 GBX  5.65%

Alto 475 GBX

Basso 315 GBX

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Haleon PLC - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

12 ratings

7

Acquista

4

Mantieni

1

Vendi

Sentiment

By Acuity

88 / 382 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Haleon PLC

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.